Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Free Report) – HC Wainwright decreased their FY2023 earnings estimates for shares of Longboard Pharmaceuticals in a report issued on Monday, January 8th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($2.28) for the year, down from their previous estimate of ($2.14). […]
Silence Therapeutics (OTCMKTS:SLNCF – Get Free Report) and Longboard Pharmaceuticals (NASDAQ:LBPH – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations. Analyst Recommendations This is a breakdown of recent […]
Cantor Fitzgerald reissued their overweight rating on shares of Longboard Pharmaceuticals (NASDAQ:LBPH – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. The firm currently has a $35.00 price objective on the stock, up from their previous price objective of $16.00. Cantor Fitzgerald also issued estimates for Longboard Pharmaceuticals’ FY2023 […]